Sandoz's Erelzi has become the first biosimilar of Amgen's Enbrel (etanercept) blockbuster inflammatory diseases drug to gain FDA approval. Erelzi (etanercept-szzs) has been approved in all uses ...

Meanwhile, since 2016 Enbrel has faced biosimilar competition in Europe. By 2020, across the European continent and the British Isles, the average market share of just the first Enbrel-referenced ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price ...